A construction project of Mingde Zhiyuan’s new research and manufacturing base has been launched on 21st of October, 2017. Sun Yi, president of Mingde Zhiyuan Pharmaceutical Co., Ltd. gave a speech on the ground breaking ceremony.The constructed new base has a land area of 103333 ㎡ and strictly complies with EU/FDA regulations. It is used for the production of freeze-dried, small volume, dripping pills and will be the key provider of Ginkgolide injection once finished in 2019.As stated in Mr Sun’s speech, it’s a new beginning for Mingde Zhiyuan –because of the higher manufacturing requirements which meet global strictest regulations, our product will benefit more patients not only in China but also over the world.